The Indian stock market is buzzing with anticipation as a whopping 112 companies prepare to unveil their Q2 financial reports on November 5th, 2025. But here's the twist: the market will be closed today due to Guru Nanak Jayanti, leaving investors eagerly awaiting the flood of earnings reports. Among the heavyweights stepping into the spotlight are Sun Pharma, Grasim Industries, Britannia Industries, Aurobindo Pharma, and Delhivery.
This week is a crucial one for Dalal Street, with over 650 companies set to disclose their Q2 FY26 results. Ajit Mishra, SVP of Research at Religare Broking Ltd., predicts that these results will significantly influence the market's trajectory. He states, 'The Q2FY26 results season will offer valuable insights into sectoral trends and corporate profitability before the festive quarter.'
Let's delve into some key expectations for a couple of these prominent companies:
Sun Pharma:
The pharmaceutical giant is forecasted to showcase stable yet modest earnings growth for the September quarter FY26. Kotak Equities projects a 130 basis point decline in EBITDA margins year-on-year and a 200 basis point drop quarter-on-quarter, reaching 27.4%. This dip can be attributed to the company's substantial investments in Leqselvi's US launch and other specialty marketing ventures. Gross margins are expected to slip to 78.8%, and R&D expenses may climb to 6.5% of sales, up from 5.5% in the previous quarter.
Britannia Industries:
Analysts predict that Britannia's volume growth will likely stagnate due to a high base effect, pricing strategies, and a temporary GST-related impact. Yes Securities estimates a 6.8% rise in revenue, driven by earlier price hikes and robust EBITDA growth. They elaborate, 'We attribute the flat base business volumes to the high base, pricing actions, and temporary GST impact. Combined with price increases from past quarters, this should result in a 6.8% revenue growth. Moderating RM inflation and the Palm oil duty cut will enhance the sequential gross margin by 120bps QoQ, while operating overhead savings will boost the EBITDA margin by ~70bps to 17.5%.'
And this is just the tip of the iceberg! The following companies are also set to release their Q2 results, each with its own unique story and potential impact on the market:
- Grasim Industries
- Aurobindo Pharma
- Tube Investments of India Ltd
- Blue Star
- Astral Limited
- Delhivery
- Honeywell Automation
- Motherson Sumi Wiring India
- Piramal Pharma
- Syngene International ...and many more, as listed in the original content.
As the earnings season unfolds, investors and market enthusiasts alike will be glued to their screens, eager to decipher the implications of these results. Will the market react positively to the earnings reports, or will there be surprises in store? Stay tuned, as the financial drama unfolds!
